Dimension Therapeutics (DMTX1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Annalisa Jenkins
Employees:
74
840 MEMORIAL DRIVE, 4TH FLOOR, CAMBRIDGE, MA 02139
617-401-0011

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Dimension Therapeutics, Inc. engages in the provision of medical development. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz on October 2013, and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 150.961 Million Shares Outstanding25.372 Million Avg 30-day Volume 52.263 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.71
Price to Revenue9.171 Debt to Equity0.2549 EBITDA-53.653 Million
Price to Book Value7.4813 Operating Margin-336.7492 Enterprise Value123.701 Million
Current Ratio2.012 EPS Growth-3.655 Quick Ratio1.703
1 Yr BETA 2.6111 52-week High/Low 0.0 / Profit Margin-336.0022
Operating Cash Flow Growth-45.4153 Altman Z-Score-3.755 Free Cash Flow to Firm -45.937 Million
View SEC Filings from DMTX1 instead.

View recent insider trading info

Funds Holding DMTX1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DMTX1

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2017-11-07:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-10-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-10-02:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-09-19:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-09-18:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-08-25:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-07-24:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-06-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-05-26:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FMR LLC

    • SEE REMARK 1
    No longer subject to file 2017-11-07 0

    MIGAUSKY GEORGE V

    • Director
    No longer subject to file 2017-11-07 0

    GEMAYEL GEORGES

    • Director
    No longer subject to file 2017-11-07 0

    COLOWICK ALAN

    • Director
    No longer subject to file 2017-11-07 0

    THISTLE MARY CHIEF OPERATING OFFICER

    • Officer
    No longer subject to file 2017-11-07 0

    MORRIS ARLENE

    • Director
    No longer subject to file 2017-11-07 0

    DYBBS MICHAEL

    • Director
    No longer subject to file 2017-11-07 0

    JENKINS ANNALISA PRESIDENT AND CEO

    • Officer
    • Director
    No longer subject to file 2017-11-07 0

    CROMBEZ ERIC CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2017-11-07 0

    WADSWORTH SAMUEL C. CHIEF SCIENTIFIC OFFICER

    • Officer
    No longer subject to file 2017-11-07 0

    HOHNEKER JOHN

    • Director
    No longer subject to file 2017-11-07 0

    FRANCHI JEAN M. CHIEF FINANCIAL OFFICER

    • Officer
    0 2017-02-01 0

    CLARK K. REED SVP OF PHARMACEUTICAL DEVELOP

    • Officer
    0 2017-02-01 0

    GUPTA RISHI

    • Director
    0 2016-05-19 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    ISALY SAMUEL D

    • Director
    • 10% Owner
    5,397,698 2015-10-27 0

    ORBIMED ADVISORS LLC

    • Director
    • 10% Owner
    0 2015-10-21 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments